Vacc-4x (Bionor Pharma) in Phase III trial with Revlimid(Celgene)for HIV treatment

Bionor Pharma announced that the clinical trial application for the placebo-controlled study with Vacc-4x in combination with Celgene`s Revlimid has been approved by the German health regulatory authorities. The study will be conducted at four different clinics in Germany, and will include HIV patients who do not recover a normal CD4 T-cell count (measurement of the immune system) despite receiving conventional HIV medicine (antiretroviral therapy, ART). The two main objectives of the study are to investigate the ability of Vacc-4x to improve the CD4 T-cell count in patients who have failed to regain these T helper cell counts to nearly normal levels despite well controlled viral load on ART, and to investigate whether Revlimid can further enhance the immune stimulating effect of Vacc-4x. The study will be conducted in Germany and coordinated by the principal investigator Prof. Jan van Lunzen, MD, who is head of Infectious Diseases and Clinical Trial Unit at the University Medical Centre Hamburg-Eppendorf.